Antibiotic Resistance: Can Rapid Tests Guide Treatment?

What Did COVID-19 Reveal About Resistance Testing?

The CDC's COVID-19 assessment documents a substantial disruption: its Antimicrobial Resistance Laboratory Network received and tested 23% fewer specimens or bacterial isolates in 2020 than in 2019. Staffing pressures, changes in care and testing backlogs complicated efforts to understand where resistance was spreading. These are historical pandemic findings, summarized on a CDC page dated February 5, 2025; they are not newly measured October 2026 infection rates. [CDC pandemic assessment](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html)

The treatment implication is that identifying a bacterium is only part of the diagnostic task. Laboratories also need to establish which medicines remain active. CDC's network supports susceptibility testing and testing for resistance mechanisms, including enzymes that disable carbapenems, an important antibiotic class. Its seven regional laboratories provide specialist capabilities that can supplement local testing. [CDC laboratory testing services](https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/testing-services.html)

How Can Resistance Tests Change Antibiotic Selection?

Molecular tests look for specific resistance genes, while antimicrobial susceptibility testing measures how bacteria respond to medicines in the laboratory. These approaches provide complementary information: a genetic result helps explain resistance, and susceptibility results help identify potentially effective treatment. CDC also offers expanded testing for selected highly resistant organisms when additional treatment information is needed. [CDC testing methods](https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/testing-services.html)

The distinction can materially change drug selection. IDSA guidance lists meropenem-vaborbactam among preferred treatments for invasive infections caused by Enterobacterales producing the KPC enzyme. Bacteria producing a different enzyme, NDM, require a different approach because vaborbactam does not inhibit NDM. The guidance identifies aztreonam-avibactam and cefiderocol as preferred options for invasive NDM-producing Enterobacterales infections, assuming demonstrated susceptibility. These examples explain why the label 'carbapenem-resistant' alone cannot determine the best medicine; the resistance mechanism and infection site also matter. [IDSA treatment guidance](https://www.idsociety.org/practice-guideline/amr-guidance/)

Do Rapid Antibiotic Tests Improve Patient Outcomes?

The multicenter RAPIDS-GN randomized trial, published in Clinical Infectious Diseases, analyzed 448 patients with Gram-negative bloodstream infections. It compared conventional laboratory testing with rapid bacterial identification and susceptibility testing; both groups received antimicrobial stewardship review. Median time to the first antibiotic modification was 8.6 hours with rapid testing versus 14.9 hours with conventional testing. This measured any antibiotic modification, rather than proving every patient received effective treatment that much earlier. [RAPIDS-GN trial](https://pubmed.ncbi.nlm.nih.gov/32374822/)

Despite faster treatment changes, the investigators reported no differences in patient outcomes between groups. The finding supports a measured interpretation: rapid diagnostics can improve the speed of prescribing decisions, but this trial did not establish a survival benefit. A reasonable practical inference is that test performance must be considered alongside how results reach clinicians and influence care. For patients, a useful discussion is whether the laboratory has identified both the organism and its susceptibility pattern. [RAPIDS-GN findings](https://pubmed.ncbi.nlm.nih.gov/32374822/)